Search Results - christopher+ruland

1 Results

Sort By:

Compositions Comprising NDGA Derivatives and Sorafenib and their Use in the Treatment of Cancer

INVENTION NOVELTYJHU investigators have combined the NDGA derivatives M4N and sorafenib to create a pharmaceutical composition that inhibits cancer cell growth. This novel drug combination has increased cytotoxic activity and inhibits growth of HCC human cancer cells in a dose-dependent manner.VALUE PROPOSITIONInvestigators have discovered a drug composition...

Published: 3/13/2025 | Inventor(s): Jong ho Chun, David Mold, Christopher Ruland, Yu-Chuan Liang, Ru Chih Huang

Keywords(s): Antagonists/Inhibitors, Cancers, Combination, Disease Indication, Novel, Predicted Novelty, Small Molecules, Targeted Therapy/Targeted Therapy, Therapeutic Matter, Therapeutic Substance, Therapeutics, Therapy Type

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities > Small Molecules, Technology Classifications > Therapeutic Modalities > Targets, Technology Classifications > Therapeutic Modalities